NASDAQ:CBLI - Cleveland BioLabs Stock Price, Forecast & News

Cleveland BioLabs' stock was trading at $3.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CBLI stock has decreased by 42.9% and is now trading at $1.80. View which stocks have been mosted impacted by Coronavirus.

Cleveland BioLabs is scheduled to release its next quarterly earnings announcement on Thursday, April 2nd 2020. View our earnings forecast for Cleveland BioLabs.

Cleveland BioLabs, Inc. (NASDAQ:CBLI) posted its quarterly earnings data on Wednesday, November, 14th. The biotechnology company reported ($0.10) earnings per share for the quarter. The biotechnology company had revenue of $0.28 million for the quarter. Cleveland BioLabs had a negative return on equity of 93.20% and a negative net margin of 241.79%. View Cleveland BioLabs' earnings history.

Media stories about CBLI stock have trended very negative on Monday, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cleveland BioLabs earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutCleveland BioLabs.

Cleveland BioLabs saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 224,300 shares, a drop of 33.7% from the February 27th total of 338,500 shares. Based on an average trading volume of 904,100 shares, the days-to-cover ratio is currently 0.2 days. Currently, 5.7% of the shares of the stock are sold short. View Cleveland BioLabs' Current Options Chain.

Some companies that are related to Cleveland BioLabs include BIOQUAL (BIOQ), Bioanalytical Systems (BASI), HedgePath Pharmaceuticals (HPPI), Tenax Therapeutics (TENX), US Stem Cell (USRM), Geovax Labs (GOVX), Vitality Biopharma (VBIO), Protalex (PRTX), ALGAE TEC LTD/S (ALGXY) and Redpoint Bio (RPBC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Tonix Pharmaceuticals (TNXP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Actinium Pharmaceuticals (ATNM), Progenics Pharmaceuticals (PGNX), Cidara Therapeutics (CDTX), Corbus Pharmaceuticals (CRBP) and NovaBay Pharmaceuticals (NBY).

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CBLI stock can currently be purchased for approximately $1.80.

Cleveland BioLabs has a market capitalization of $20.34 million and generates $1.14 million in revenue each year.  View additional information about Cleveland BioLabs.

The official website for Cleveland BioLabs is http://www.cbiolabs.com/.

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]